Complete Story
04/16/2019
Important Oncology Related News
HCPCS Quarterly Update - New C-codes and J-codes effective April 1, 2019
CMS has released additional C-codes and J-codes effective April 1, 2019. To download the files and review the changes CLICK HERE.
Look under: Other Codes (other than C and G HCPCS codes)
*Revised Other New Codes Published 4-5-2019 Effective 7-1-2019 [ZIP, 9KB]
*Other New Codes Published 4-4-2019 Effective 7-1-2019 [ZIP, 10KB]
Review Your Quality Payment Program Performance Information Before it is Publicly Reported
(ASCO in Action) Apr 5, 2019 - This is the first year that Quality Payment Program performance information will be publicly reported, and many stakeholders asked the Centers for Medicare & Medicaid Services (CMS) for additional time to review their data before it becomes available to the public.
Medicaid Reimbursement To Treat Cancer Patients With Radiation Therapy Varies Widely, Study Shows
(ASTRO) Apr 11, 2019 - A new study finds wide state-by-state variations in Medicaid reimbursements to physicians who treat cancer patients with radiation therapies.
Doctors’ Group Cannot Sue Over Cuts To Medicare Drug Reimbursements
Apr 1, 2019 - A federal judge in Washington, D.C. has ruled that an association of oncologists cannot pursue a lawsuit challenging a 2 percent cut in reimbursements by Medicare for medications administered by healthcare providers including cancer drugs. READ ARTICLE
The PAN Foundation Opens New Carcinoid Syndrome Patient Assistance Fund
Washington, D.C., April 17, 2019—The PAN Foundation today opened a new patient assistance program for people living with carcinoid syndrome. Carcinoid syndrome occurs when an underlying carcinoid tumor produces excessive amounts of serotonin, often due to liver metastases. READ MORE
Updated ASCO and ASH Guidelines on Managing Anemia Support Safety, Efficacy of Biosimilar ESAs
(The Center For Biosimilars) Apr 16, 2019 - The American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) have issued an updated practice guideline on the use of erythropoiesis-stimulating agents (ESAs) in cancer care in which they state that the available literature suggest that biosimilars of epoetin alfa have similar efficacy and safety to reference agents and that both biosimilars and their references may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent.
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
